News

BioSpace25m

Oral Wegovy’s Pending Approval Puts Spotlight on Viability of High-Dose Peptides

While the 10-fold increase in dose over injectable Wegovy has raised questions about the launch, Novo Nordisk has assured ...

Why Novo Nordisk Stock Popped Monday

Shares of Novo Nordisk ( NVO 4.81%), the Danish pharmaceuticals company famed for Ozempic and Wegovy weight loss drugs, ...

Wegovy News Pushes Novo Nordisk Stock Higher

Novo Nordisk stock rose after good news from the FDA on Wegovy—it’s popular weight-loss drug which has the same active ...

Stocks to Watch Monday: Novo Nordisk, TeraWulf, UnitedHealth, Soho House

The Food and Drug Administration approved Novo Nordisk’s popular weight-loss drug Wegovy to treat a [form of liver disease]( ...

Novo Nordisk stock soar 5% today: here’s why analysts are bullish

Novo Nordisk stock gains as FDA expands Wegovy use, while Ozempic price cut aims to boost access and defend market share.

Novo Nordisk to offer Ozempic at $499 per month to eligible US customers

Novo Nordisk said on Monday it was offering its diabetes drug Ozempic for $499 per month to eligible cash-paying type 2 ...
Zacks.com on MSN3d

Will New CEO's Leadership Propel Novo Nordisk's Next Growth Wave?

Maziar Mike Doustdar takes office as NVO's new CEO, bringing a proven global growth record to tackle rising obesity market ...